ONCAlert | Upfront Therapy for mRCC
Latest NewsMORE >>
The FDA has approved niraparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with ≥3 prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency positivity.
Videos
Latest JournalAll Journals >>
Targeted Therapies in Oncology October 2 2019
MORE >>